Cetrelimab
- CAS No.
- 2050478-92-5
- Chemical Name:
- Cetrelimab
- Synonyms
- Cetrelimab;Cetrelimab (anti-PDCD1);Research Grade Cetrelimab;Research Grade Cetrelimab(DHH02204)
- CBNumber:
- CB28081085
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | LYK98WP91F |
| NCI Drug Dictionary | cetrelimab |
Cetrelimab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0628014 | Cetrelimab ≥99.0% | 2050478-92-5 | 1mg | $325 | 2026-06-04 | Buy |
| ChemScene | CS-0628014 | Cetrelimab ≥99.0% | 2050478-92-5 | 5mg | $845 | 2026-06-04 | Buy |
| ChemScene | CS-0628014 | Cetrelimab ≥99.0% | 2050478-92-5 | 10mg | $1354 | 2026-06-04 | Buy |
| aablocks | AA02A884 | Cetrelimab ≥95%(SDS-PAGE&SEC-HPLC) | 2050478-92-5 | 1mg | $572 | 2026-06-02 | Buy |
| aablocks | AA02A884 | Cetrelimab ≥95%(SDS-PAGE&SEC-HPLC) | 2050478-92-5 | 5mg | $1334 | 2026-06-02 | Buy |
Cetrelimab Chemical Properties, Uses, Production
Uses
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo[1].
in vivo
Cetrelimab (10 mg/kg; i.p.; single dose) has antitumor efficacy, and decreases tumor volume in PD-1 knock-in (hPD-1KI) mice with MC38 tumor[1].
Cetrelimab (10 mg/kg; i.p.; once every 5 days for 30 d) results significant increases in peripheral blood CD8+ T cells in patient-derived xenograft (PDX) lung model in mice[1].
Cetrelimab (10-100 mg/kg; i.v.; once weekly for 5 weeks) has well tolerance in cynomolgus model[1].
Cetrelimab (0.1-10 mg/kg; i.v.; single dose, monitored for 57 d) shows an nonlinear pharmacokinetics (PK) in cynomolgus, possibly attributable to target-mediated drug deposition (TMDD)[1].
| Animal Model: | hPD-1KI model with mouse PD-1 ECD replaced by the human PD-1 ECD[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; single dose at day 7 after tumor implantation |
| Result: | hPD-1KI mice develop normally and have no immune abnormalities. Significantly lowered tumor volume at Day 21. |
| Animal Model: | Patient-derived xenograft (PDX) LG1306 lung model in mice[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; every 5 days for 6 cycles |
| Result: | Significantly reduced patient-derived tumor volume by 32%. |
| Animal Model: | Good Laboratory Practice (GLP) toxicity study in cynomolgus[1] |
| Dosage: | 0, 10, 30, or 100 mg/kg |
| Administration: | Intravenous injection; once weekly for 5 weeks |
| Result: | Showed well tolerance in cynomolgus. |
References
[1] DeAngelis N, et al. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models. Cancer Chemother Pharmacol. 2022 Apr;89(4):515-527. DOI:10.1007/s00280-022-04415-5
Cetrelimab Preparation Products And Raw materials
Raw materials
Preparation Products
Cetrelimab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
| Wuhan Acumen Bio-Technology Co.,ltd | 027-027-16602739303 16602739303 | 673003916@qq.com | China | 4593 | 58 |
